Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial.
Saved in:
| Title: | Causal effects of psychostimulants on neural connectivity: a mechanistic, randomized clinical trial. |
|---|---|
| Authors: | Wang, Yun, Kessel, Ellen, Lee, Seonjoo, Hong, Susie, Raffanello, Elizabeth, Hulvershorn, Leslie A., Margolis, Amy, Peterson, Bradley S., Posner, Jonathan |
| Source: | Journal of Child Psychology & Psychiatry. Nov2022, Vol. 63 Issue 11, p1381-1391. 11p. 2 Diagrams, 1 Chart, 3 Graphs. |
| Subjects: | Brain, Central nervous system stimulants, Neurons, Functional connectivity, Magnetic resonance imaging, Attention-deficit hyperactivity disorder, Randomized controlled trials, Comparative studies, Dextroamphetamine, Statistical sampling, Pharmacodynamics |
| Abstract: | Background: Psychostimulants are frequently used to treat attention‐deficit/hyperactivity disorder (ADHD), but side effects are common leading to many patients discontinuing treatment. Identifying neural mechanisms by which psychostimulants attenuate symptoms may guide the development of more refined and tolerable therapeutics. Methods: We conducted a 12‐week, randomized, placebo‐controlled trial (RCT) of a long‐acting amphetamine, lisdexamfetamine (LDEX), in patients with ADHD, ages 6–25 years old. Of the 58 participants who participated in the RCT, 49 completed pre‐ and post‐RCT magnetic resonance imaging scanning with adequate data quality. Healthy controls (HCs; n = 46) were included for comparison. Treatment effects on striatal and thalamic functional connectivity (FC) were identified using static (time‐averaged) and dynamic (time‐varying) measures and then correlated with symptom improvement. Analyses were repeated in independent samples from the Adolescent Brain Cognitive Development study (n = 103) and the ADHD‐200 Consortium (n = 213). Results: In 49 participants (25 LDEX; 24 Placebo), LDEX increased static and decreased dynamic FC (DFC). However, only DFC was associated with the therapeutic effects of LDEX. Additionally, at baseline, DFC was elevated in unmedicated‐ADHD participants relative to HCs. Independent samples yielded similar findings – ADHD was associated with increased DFC, and psychostimulants with reduced DFC. Static FC findings were inconsistent across samples. Conclusions: Changes in dynamic, but not static, FC were associated with the therapeutic effects of psychostimulants. While prior research has focused on static FC, DFC may offer a more reliable target for new ADHD interventions aimed at stabilizing network dynamics, though this needs confirmation with subsequent investigations. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Child Psychology & Psychiatry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background: Psychostimulants are frequently used to treat attention‐deficit/hyperactivity disorder (ADHD), but side effects are common leading to many patients discontinuing treatment. Identifying neural mechanisms by which psychostimulants attenuate symptoms may guide the development of more refined and tolerable therapeutics. Methods: We conducted a 12‐week, randomized, placebo‐controlled trial (RCT) of a long‐acting amphetamine, lisdexamfetamine (LDEX), in patients with ADHD, ages 6–25 years old. Of the 58 participants who participated in the RCT, 49 completed pre‐ and post‐RCT magnetic resonance imaging scanning with adequate data quality. Healthy controls (HCs; n = 46) were included for comparison. Treatment effects on striatal and thalamic functional connectivity (FC) were identified using static (time‐averaged) and dynamic (time‐varying) measures and then correlated with symptom improvement. Analyses were repeated in independent samples from the Adolescent Brain Cognitive Development study (n = 103) and the ADHD‐200 Consortium (n = 213). Results: In 49 participants (25 LDEX; 24 Placebo), LDEX increased static and decreased dynamic FC (DFC). However, only DFC was associated with the therapeutic effects of LDEX. Additionally, at baseline, DFC was elevated in unmedicated‐ADHD participants relative to HCs. Independent samples yielded similar findings – ADHD was associated with increased DFC, and psychostimulants with reduced DFC. Static FC findings were inconsistent across samples. Conclusions: Changes in dynamic, but not static, FC were associated with the therapeutic effects of psychostimulants. While prior research has focused on static FC, DFC may offer a more reliable target for new ADHD interventions aimed at stabilizing network dynamics, though this needs confirmation with subsequent investigations. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00219630 |
| DOI: | 10.1111/jcpp.13585 |
